Stockscreener 앱 받기
14.22
3.27%
0.45
전일 마감가:
$13.77
열려 있는:
$13.96
하루 거래량:
9,012
Relative Volume:
0.76
시가총액:
$1.00B
수익:
$370.44M
순이익/손실:
$12.19M
주가수익비율:
82.53
EPS:
0.1723
순현금흐름:
$50.74M
1주 성능:
+6.12%
1개월 성능:
+13.39%
6개월 성능:
-15.66%
1년 성능:
+34.40%
1일 변동 폭
$13.78
$14.17
1주일 범위
$13.47
$14.17
52주 변동 폭
$9.5354
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
14.17 | 980.98M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
526.36 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.88 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
927.48 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
314.92 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.80 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-12-09 | 개시 | Jefferies | Buy |
Pharming Group Nv Adr 주식(PHAR)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
PHARPharming Group NV ADR Stock Price and Quote - Finviz
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Pharming Group N.V. Investigated by the Portnoy Law Firm - GlobeNewswire
Pharming (NASDAQ: PHAR) updates 20-F with corrected CEO/CFO certifications - Stock Titan
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 33.9% in March - MarketBeat
Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright - defenseworld.net
HC Wainwright Estimates Pharming Group Q3 Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest - MarketBeat
HC Wainwright Predicts Pharming Group Q1 Earnings - MarketBeat
A2QLQY Stock Price and Chart — LS:A2QLQY - TradingView
Wainwright reiterates Pharming stock Buy rating on commercial growth - Investing.com
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Finviz
Pharming Group Nv Adr (PHAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
0.50%
자본화:
|
볼륨(24시간):